EUVIMEDEuropean Health Evidence
Uhr 10/10Sources Journal Tree
Easy Demo

Lokaler Crossref-Datenbestand · journal-article

Suspected retention of magnesium oxide tablets during co-administration with recovery K5, a concentrated oral enteral nutrition formula, supported by in vitro disintegration testing

Makoto Ohira, Hirohisa Fujitsuka, Rin Ono, Hikari Terui, Masanori Motegi, Susumu Kurushima, Tatsuru Ota, Toshikazu Kitagawa, Ryosuke Shinkai, Takahiro Amemiya, Takashi Tomita, Kenji Sumiya

Journal of Pharmaceutical Health Care and Sciences · 2026

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Abstract Background Concentrated oral enteral nutrition (EN) formulas are used when adequate energy intake is required despite limited feeding volume, but their compatibility with tablets has not been fully evaluated. We observed computed tomography (CT) findings suggestive of gastrointestinal retention of magnesium oxide (MgO) tablets in an older inpatient receiving concentrated EN and performed an exploratory in vitro disintegration study. Methods Clinical medication, nutrition, and CT data were reviewed retrospectively. The CT attenuation and diameter of intraluminal tablet-like structures were compared with those of an intact MgO tablet scanned in water. For in vitro testing, MgO tablets were evaluated using Japanese Pharmacopoeia-based disintegration testing in purified water, simulated gastric fluid, and simulated intestinal fluid, with or without 30-min pre-exposure to Recovery K5, a concentrated oral EN formula. Direct disintegration in Recovery K5 was also examined as a worst-case condition. Results were summarized descriptively. Results CT showed three discrete high-attenuation intraluminal structures measuring 9.0–9.4 mm and 501–880 HU, findings compatible with suspected undisintegrated MgO tablets. Without pre-exposure, MgO tablets disintegrated within 8–10 s. After pre-exposure to Recovery K5, mean disintegration times increased to 338.5–422.2 s. In Recovery K5 itself, tablets remained incompletely disintegrated beyond 10,020 s. Conclusions This brief report does not establish definitive causality, but it identifies a clinically relevant signal supported by in vitro evidence. These findings support pharmacist-led review of the actual administration sequence, water volume, and dosage-form selection when MgO tablets are administered concomitantly with Recovery K5, a concentrated oral EN formula.

Bibliografischer Nachweis

Publikationsdaten

Autor:innen
Makoto Ohira, Hirohisa Fujitsuka, Rin Ono, Hikari Terui, Masanori Motegi, Susumu Kurushima, Tatsuru Ota, Toshikazu Kitagawa, Ryosuke Shinkai, Takahiro Amemiya, Takashi Tomita, Kenji Sumiya
Quelle
Journal of Pharmaceutical Health Care and Sciences
Publikation
2026-01-01
Band / Ausgabe
Nicht angegeben
Seiten
Nicht angegeben
ISSN / ISBN
2055-0294
Zitationen
0 laut Crossref
Referenzen
0 hinterlegt

Zitieren

Zitierfähiger Nachweis

Makoto Ohira, Hirohisa Fujitsuka, Rin Ono, Hikari Terui, Masanori Motegi, Susumu Kurushima, Tatsuru Ota, Toshikazu Kitagawa, Ryosuke Shinkai, Takahiro Amemiya, Takashi Tomita, Kenji Sumiya (2026). Suspected retention of magnesium oxide tablets during co-administration with recovery K5, a concentrated oral enteral nutrition formula, supported by in vitro disintegration testing. Journal of Pharmaceutical Health Care and Sciences. https://doi.org/10.1186/s40780-026-00620-z
RIS BibTeX CSL-JSON

Kontext

Themen, Förderung und Nutzung

Lizenzhinweise: Lizenz 1